Skip to main content


Volume 3 Supplement 1


Burden of septic shock in the uk

Article metrics

  • 249 Accesses


Septic shock is a major health care problem which affects between 20-30 million people per year worldwide.[1]


The objective of this study was to analyse the burden of septic shock in 2012 for England, Wales and Northern Ireland.


We analyzed length of stay, survival and organ support of adult septic shock patient admitted to general critical care units. Septic shock was defined as severe sepsis including the presence of cardiovascular organ dysfunction (from cardiovascular SOFA Score of 2, 3 or 4). Physiological definitions were matched as closely as possible to those used in the PROWESS trial.[2]

These data derive from the Case Mix Programme Database. The Case Mix Programme is the national, comparative audit of patient outcomes from adult critical care coordinated by the Intensive Care National Audit & Research Centre (ICNARC). These analyses are based on data for 136,880 admissions to 205 adult, general critical care units based in NHS hospitals geographically spread across England, Wales and Northern Ireland. For more information on the representativeness and quality of these data, please contact ICNARC.


Tables 1 and 2.

Table 1 Case mix and mortality of admissions.
Table 2 Length of hospital stay and organ support in 2012.


It is evident that patients who develop septic shock pose a heavy burden to the UK society, as well as to the NHS hospitals. One in every six patient admitted to a critical care unit is diagnosed with septic shock. Nearly 40 percent ultimately die while staying at the hospital, of which close to 30 percent die during CCU stay. These patients also require substantial renal and respiratory support, as well as total hospital stays of up to a month. Septic shock is a very burdensome and costly illness and every effort should be made to reduce this burden to the patients, hospitals and society.

Grant Acknowledgment

FA and ALK are employed by Ferring Pharmaceuticals. At the time of the study, TK was employed by Ferring Pharmaceuticals.


  1. 1.

    Dellinger , et al: Crit Care Med. 2013, 41: 580-637.

  2. 2.

    Bernard GR, et al: NEJM. 2001, 344: 699-709.

Download references

Author information

Correspondence to AL Kjølbye.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Andersson, F., Kristensen, T. & Kjølbye, A. Burden of septic shock in the uk. ICMx 3, A154 (2015) doi:10.1186/2197-425X-3-S1-A154

Download citation


  • Septic Shock
  • Septic Shock Patient
  • Grant Acknowledgment
  • Ferring Pharmaceutical
  • Prowess Trial